Twist Bioscience (NASDAQ:TWST) Stock Price Target Lowered at TD Cowen

Key Points

• TD Cowen cut its price target on Twist Bioscience from $190 to $137 but maintained a Buy rating; the new target implies 24.7% upside from the prior close.
• Analyst views are mixed: seven rate the stock Buy, three Hold, and two Sell, with an average rating of Hold and an average price target of $145.
• Twist reported quarterly revenue of $126.6 million, up 26.7% year over year and above estimates, while its $0.32-per-share loss was narrower than expected.

Twist Bioscience (NASDAQ:TWST - Get Free Report) had its price target reduced by research analysts at TD Cowen from $190.00 to $137.00 in a research note issued on Friday, Benzinga reports. The firm currently has a "buy" rating on the stock. TD Cowen's target price suggests a potential upside of 24.71% from the stock's previous close.

A number of other research firms also recently weighed in on TWST. BWS Financial restated a "sell" rating and issued a $45.00 target price on shares of Twist Bioscience in a research report on Friday, September 18th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Twist Bioscience in a research report on Monday, September 21st. Barclays lifted their price target on Twist Bioscience from $112.00 to $215.00 and gave the company an "overweight" rating in a research report on Wednesday, October 7th. Jefferies Financial Group initiated coverage on Twist Bioscience in a research note on Thursday, October 8th. They issued a "hold" rating and a $150.00 price objective on the stock. Finally, Piper Sandler upped their price objective on Twist Bioscience from $85.00 to $115.00 and gave the company an "overweight" rating in a report on Wednesday, August 5th. Seven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Twist Bioscience has an average rating of "Hold" and an average price target of $145.00.

Twist Bioscience Stock Performance

Shares of NASDAQ TWST traded down $4.37 during midday trading on Friday, reaching $109.85. 318,673 shares of the company traded hands, compared to its average volume of 1,781,233. Twist Bioscience has a 52 week low of $23.30 and a 52 week high of $219.71. The stock has a 50-day moving average price of $150.57 and a 200 day moving average price of $92.73. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The company has a market cap of $6.89 billion, a price-to-earnings ratio of -49.83 and a beta of 2.25.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.39) by $0.07. The firm had revenue of $126.64 million during the quarter, compared to analyst estimates of $123.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The business's quarterly revenue was up 26.7% compared to the same quarter last year. Sell-side analysts anticipate that Twist Bioscience will post -2.11 earnings per share for the current fiscal year.

Insider Activity

In other Twist Bioscience news, CAO Robert Werner sold 1,482 shares of Twist Bioscience stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $279,920.16. Following the transaction, the chief accounting officer owned 42,917 shares in the company, valued at approximately $8,106,162.96. The trade was a 3.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Dennis Cho sold 949 shares of the company's stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $135.40, for a total value of $128,494.60. Following the completion of the transaction, the insider directly owned 62,840 shares in the company, valued at $8,508,536. This represents a 1.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 495,279 shares of company stock valued at $80,489,387 in the last ninety days. 3.08% of the stock is owned by company insiders.

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors and hedge funds have recently modified their holdings of TWST. Abacus Wealth Partners LLC boosted its position in shares of Twist Bioscience by 4.3% in the 3rd quarter. Abacus Wealth Partners LLC now owns 2,332 shares of the company's stock valued at $451,000 after purchasing an additional 96 shares during the period. Root Financial Partners LLC purchased a new position in Twist Bioscience in the 3rd quarter worth about $33,000. GAMMA Investing LLC raised its holdings in Twist Bioscience by 24.4% during the 2nd quarter. GAMMA Investing LLC now owns 943 shares of the company's stock worth $97,000 after buying an additional 185 shares during the period. Abel Hall LLC raised its holdings in Twist Bioscience by 3.6% during the 3rd quarter. Abel Hall LLC now owns 5,514 shares of the company's stock worth $1,066,000 after buying an additional 191 shares during the period. Finally, Allworth Financial LP raised its holdings in Twist Bioscience by 54.9% during the 2nd quarter. Allworth Financial LP now owns 601 shares of the company's stock worth $62,000 after buying an additional 213 shares during the period.

More Twist Bioscience News

Here's some of the latest news about TWST:

• Positive Sentiment: Fiscal Q4 revenue was $126.6 million, up about 28% year over year and above expectations; the loss of $0.32 per share was also narrower than the cited consensus estimate. Article: Twist Bioscience Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Q1 fiscal 2027 revenue guidance of $130 million–$132 million tops the $126.3 million consensus, offering a near-term sign of continued growth. Article: Twist Bioscience Earnings Results
• Neutral Sentiment: Fiscal 2027 revenue guidance of $550 million–$560 million is only slightly above the $549 million consensus. Although technically a beat, reports characterized the outlook as underwhelming, suggesting investors wanted stronger indications of future growth. Article: Twist Bio Slips Despite Q4 Beat After Underwhelming FY27 Outlook

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.